Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ver-A-Long open-label extension of verapamil SR in adults with type 1 diabetes
2024-515234-33-00Phase 2Authorised
- Sponsor
- Medical University of Graz
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of verapamil in diabetes mellitus type 1 (T1D), sponsored by Medical University of Graz. Primary endpoint: Change in C-peptide AUC percent change at 24 months. Planned start Nov 2024; status: authorised.
02
Drugs
verapamil
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2024-515234-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515234-33-00.